.

BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
UBS
McKinsey
Mallinckrodt
Medtronic
Deloitte
Cipla
Dow
Express Scripts
Citi

Generated: September 24, 2017

DrugPatentWatch Database Preview

NEXIUM IV Drug Profile

« Back to Dashboard

What is the patent landscape for Nexium Iv, and what generic Nexium Iv alternatives are available?

Nexium Iv is a drug marketed by Astrazeneca Pharms and is included in one NDA.

The generic ingredient in NEXIUM IV is esomeprazole sodium. There are sixty-seven drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the esomeprazole sodium profile page.

Summary for Tradename: NEXIUM IV

Patents:0
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list107
Clinical Trials: see list68
Patent Applications: see list3,261
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:NEXIUM IV at DailyMed

Pharmacology for Tradename: NEXIUM IV

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Astrazeneca Pharms
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689-001Mar 31, 2005DISCNYesNo► Subscribe► Subscribe► Subscribe
Astrazeneca Pharms
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689-002Mar 31, 2005APRXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: NEXIUM IV

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca Pharms
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689-001Mar 31, 2005► Subscribe► Subscribe
Astrazeneca Pharms
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689-002Mar 31, 2005► Subscribe► Subscribe
Astrazeneca Pharms
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689-001Mar 31, 2005► Subscribe► Subscribe
Astrazeneca Pharms
NEXIUM IV
esomeprazole sodium
INJECTABLE;INTRAVENOUS021689-002Mar 31, 2005► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for NEXIUM IV

Drugname Dosage Strength RLD Submissiondate
esomeprazole sodiumFor Injection20 mg/vial and 40 mg/vialNexium IV11/23/2009
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chinese Patent Office
Colorcon
Argus Health
Boehringer Ingelheim
Mallinckrodt
Accenture
Deloitte
Cipla
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot